Login to Your Account



Coherus Advances Biosimilars Model; Inks Daiichi Deal in Asia

By Jennifer Boggs
Managing Editor

Tuesday, May 8, 2012
Capitalizing on a wealth of biologics expertise, 2010 start-up Coherus BioSciences Inc. is moving into the global biosimilars space, kicking off its efforts with an Asian partnership with Daiichi Sankyo Co. Ltd. to develop and commercialize biosimilar versions of Enbrel (etanercept, Amgen Inc.) and Rituxan (rituximab, Biogen Idec Inc. and Roche AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription